Medigene to Present at Upcoming Scientific Conferences
October 16, 2024 05:30 ET
|
Medigene AG
Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 10, 2024 21:00 ET
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
October 04, 2024 10:31 ET
|
Compass Therapeutics
BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Nouscom to Present Updated Positive Data on NOUS-209’s Potential to ‘Intercept’ Cancer in Lynch Syndrome Carriers at SITC 2024
October 04, 2024 09:00 ET
|
Nouscom Srl
BASEL, Switzerland – 4th October 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, announces...
Mendus presenterar uppdaterad data från ALISON-studien med vididencel i äggstockscancer vid SITC 2023
November 06, 2023 02:00 ET
|
Mendus AB
Pressmeddelande Stockholm, 6 november 2023 Mendus AB (“Mendus” publ; IMMU. ST), ett biofarmabolag med fokus på immunterapier riktade mot tumöråterfall, meddelade idag publiceringen av uppdaterade...
Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
November 06, 2023 02:00 ET
|
Mendus AB
Press Release Stockholm, Sweden, November 6, 2023 Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence,...
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11
November 04, 2023 12:00 ET
|
Medigene AG
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
November 03, 2023 14:00 ET
|
ImCheck Therapeutics SAS
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023 Interim data from EVICTION-2 study confirms safety and tolerability...
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
November 03, 2023 12:01 ET
|
HOOKIPA Pharma Inc.
HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were...
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting
November 03, 2023 03:58 ET
|
Glycotope
Glycotope Presents anti-GlycoTarget Antibodies at the 2023 Society for Immunotherapy of Cancer (SITC) Meeting Berlin, Germany, 03 November, 2023 – Glycotope GmbH, a biotechnology company with a...